Back to Authors

Fakih, Riad El

Mayo Clinic

King Faisal Specialist Hospital & Research Centre

Citations 1

Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies
Makni-Maalej, Karama, Alotaibi, Shaykhah Mujahhiz, Ahmed, Syed Osman, Mestiri, Sarra , Amir, Waad, Farhatullah, Syed, Kharfan-Dabaja, M., Fakih, Riad El, Aljurf, Mahmoud, Makni‐Maalej, Karama , Alotaibi, Shaykhah , Fernandes, Queenie , Mestiri, Sarra, Bougarn, Salim , Syed, Farhatullah , Kharfan‐Dabaja, Mohamed A. , Merhi, Maysaloun , Fakih, Riad El , Aljurf, Mahmoud , Dermime, Said

Frontiers in Immunology | February 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1762453 Get It

T cell fitness has emerged as a critical determinant of the efficacy and persistence of Chimeric Antigen Receptor (CAR)-T cell therapy. Defined by the capacity of T cells to proliferate, resist exhaustion, persist in vivo , and exert sustained effector functions, T cell fitness reflects the integration of a dynamic network of intrinsic and extrinsic regulatory mechanisms. In this review, we present a comprehensive synthesis of the molecular and cellular foundations underlying T cell fitness, emphasizing the influence of differentiation trajectories, signaling pathways, metabolic reprogramming, and epigenetic modifications. We further discuss the impact of patient-specific conditions such as age as well as disease biology, prior therapeutic exposures, and timing and quality of T cell collection, on the phenotypic and functional efficacy of CAR-T cell products. Beyond delineating these determinants, we highlight emerging strategies aimed at enhancing T cell fitness. Importantly, we propose T cell fitness as an integrated, multi-layered systems property emerging from the interaction between differentiation state, signaling architecture, metabolic–mitochondrial competence, epigenetic stability, and host-specific inflammatory and treatment-related pressures. We introduce a mechanistic framework that links these layers across the CAR-T therapeutic timeline from leukapheresis to post-infusion tumor engagement and outline how this framework can be operationalized into measurable parameters to guide patient stratification, manufacturing decisions, and rational therapeutic interventions.